Ubs Asset Management Americas Inc Arcutis Biotherapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $381 Billion
- Q3 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 276,691 shares of ARQT stock, worth $2.56 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
276,691
Previous 273,779
1.06%
Holding current value
$2.56 Million
Previous $2.55 Million
1.06%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ARQT
# of Institutions
197Shares Held
129MCall Options Held
738KPut Options Held
82K-
Jennison Associates LLC11.7MShares$108 Million0.07% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$102 Million2.84% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.7MShares$99.3 Million3.92% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$81.4 Million4.4% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$79.8 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $557M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...